-
Mashup Score: 5Management of chronic myeloid leukemia in 2023 – common ground and common sense - Blood Cancer Journal - 2 year(s) ago
With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-generation TKIs (bosutinib, dasatinib and nilotinib) are associated with comparable survival results. The…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4ASCO Congratulates 2023 Special Awards Recipients - 2 year(s) ago
ASCO and Conquer Cancer will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting.
Source: ASCO ConnectionCategories: Hem/Oncs, Latest HeadlinesTweet-
Karnofsky top @ASCO award recognizes @MDAndersonNews #Leukemia Faculty team research and excellence. 10 are among top 15 world leukemia researchers. https://t.co/fSiQjZVVgk #leusm #EndCancer #ASCO2023 https://t.co/C2epOkGmYb
-
-
Mashup Score: 5
Revumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, is associated with a low frequency of treatment-related adverse events and promising clinical activity in patients with relapsed or refractory acute leukaemia.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest targeted therapy in leukemia. First clinical evidence of responses with menin inhibitors in very resistant leukemias Ghayas Issa @GhayasIssa of @MDAndersonNews #Leukemia https://t.co/oqHzm7GJC8 @Nature #leusm https://t.co/Guq2IhkF48
-
-
Mashup Score: 0Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity - 2 year(s) ago
Key Points. Treatment intensity was not significantly associated with OS or CIR by multivariate analysis in patients with AML responding to therapyAchievement o
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
ELN risk and MRD status supersede treatment intensity in predicting outcomes in patients with #AML achieving a response Alexandre Bazinet of @MDAndersonNews #Leukemia | @BloodAdvances @ASH_Hematology https://t.co/CYqxzDbqb3 #leusm https://t.co/MizLoPXuqT
-
-
Mashup Score: 1North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need - 2 year(s) ago
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment appro
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Sharing our new major effort: North American #BPDCN Consortium to highlight increased collaboration & novel patient-based research approaches | Pemmaraju of @MDAndersonNews #Leukemia | https://t.co/GjIieJJEAH via @BloodJournal @ASH_hematology #leusm https://t.co/AA7wShgUjh
-
-
Mashup Score: 44Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL. Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia https://t.co/gKPyzpRiiI via @TheLancetHaem #leusm https://t.co/j92ASgErbo
-
-
Mashup Score: 7Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia - 2 year(s) ago
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy development. Though most patients with CML have a normal quality and duration of life with TKI therapy, some patients progress to accelerated phase (AP) and blast phase (BP), both of which have a relatively poor prognosis. The rates of progression have reduced significantly…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New review on state-of-the-art treatment of advanced phase #CML (AP/BP) by @JayastuMD and @NicholasShort of @MDAndersonNews #Leukemia, published in @LeukemiaJnl. We prefer ponatinib-based combo regimens for these pts whenever possible. https://t.co/pZTO8HWWkM #leusm https://t.co/w9ReGvr29N
-
-
Mashup Score: 22Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML - 2 year(s) ago
Key Points. In relapsed or refractory acute myeloid leukemia, mutated NPM1 has no impact on risks of relapse or death.The addition of venetoclax to salvage trea
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Outcomes of NPM1+ #AML at relapse are not favorable. Recommend new therapies such as menin inhibitors. @GhayasIssa @ABidikianMD @Daver_Leukemia of @MDAndersonNews #Leukemia https://t.co/H5xYJAnjfr via @ASH_hematology @BloodAdvances #ASH22 #leusm https://t.co/3Hpgk4AbuP
-
-
Mashup Score: 4
Measurable residual disease (MRD) is associated with relapse and survival in acute myeloid leukemia (AML). We aimed to quantify the impact of MRD on outcomes across clinical contexts, including its association with hematologic response and MRD assay sensitivity. We performed systematic literature review and meta-analysis of 48 studies that reported the association between MRD and overall survival…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
New meta-analysis: MRD highly prognostic in #AML, regardless of type of response (CR vs. others) or assay sensitivity. More evidence that MRD could be surrogate endpoint in AML | @NicholasShortMD @MDAndersonNews #Leukemia https://t.co/VoEKlVAO5W @LeukemiaJnl #leusm https://t.co/UCeBg6EWHz
-
-
Mashup Score: 19Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes - PubMed - 2 year(s) ago
Activating mutations in RAS have been reported in about 10-15% of patients with AML; previous studies have not identified a prognostic significance. However, RAS mutations have emerged as a potential resistance mechanism to treatment with inhibitors of FLT3, IDH, and BCL2. We aimed to determine the …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
New diagnosis #AML and RAS mutation = favorable outcome with araC regimens, and with hypomethylating agents + venetoclax | Tapan Kadia @TapKadia and Kantarjian of @MDAndersonNews #Leukemia https://t.co/ru5AcQ4aEv via @AjHematology #leusm https://t.co/MN46FX1MXm
-
Discussing treatment choices and endpoints in #CML: what is best for the patient in 2023? Please check out our review just published in @BloodCancerJnl. @jayastuMD of @MDAndersonNews #Leukemia https://t.co/ycxgWYvTqK #leusm https://t.co/93GqIZriqV